Ozempic has entered the group chat. Since GLP-1 agonist drugs burst onto the scene, they've been hailed as a weight-loss game changer, but they've also raised uncomfortable questions about what bodies are acceptable, or not.For years, the body inclusivity movement pushed back against the idea that only thin bodies can be 'healthy' but Ozempic & co are drowning out this message.So, what do these drugs mean for fat liberation? And how can we shift our collective thinking around weight and morality?Yumi Stynes chats to a panel of amazing women about the impact of this new generation of weight-loss drugs and how we can all find ways to be kinder to our bodies.Featured in this conversation:Dr Emma Beckett, nutritionistEvie Gardiner, size inclusivity advocateNat Atkinson, Mum, taking WegovyYou might also like:The Ozempic eraI'm fat, don't hate me—Aubrey GordonFat talkThis episode contains references to fat, fatphobia, weight stigma, Ozempic, Wegovy, Mounjaro, GLP-1 agonists, semaglutide, obesity, diet, diet culture, women, body image, self-esteem, bullying, weight loss, Serena Williams.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related